Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that the Company will present at The Microcap Rodeo Winter Wonderland Conference on February 17, 2021 at 2:30pm EST.
Corporate Presentation to be Webcast on February 17, 2021
ENGLEWOOD, Colo., Feb. 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that the Company will present at The Microcap Rodeo Winter Wonderland Conference on February 17, 2021 at 2:30pm EST. This conference is virtual.
To access the webcast, please log in to the following link approximately 10 minutes prior to the start of the presentation time: https://www.webcaster4.com/Webcast/Page/2134/40042.
About Ampio Pharmaceutical, Inc.
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of AmpionTM, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, AmpionTM, is backed by an extensive patent portfolio with intellectual property protection extending through 2032, and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (“BPCIA”).
Forward Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to AmpionTM and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (“BLA”), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that AmpionTM may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Investor Relations
Joe Hassett
joeh@gregoryfca.com
484-686-6600
Media Contact
Sarah May
sarahm@gregoryfca.com
215-205-1217
View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-present-at-upcoming-investor-conference-301228759.html
SOURCE Ampio Pharmaceuticals, Inc.
Company Codes: AMEX:AMPE
